Examining the safety and efficacy of a chemotherapy dosing method in Allogeneic Stem Cell Transplant patients of extreme body size

Journal of Oncology Pharmacy Practice

Volumn 15, Issue 4, 2009, Pages 201-210

  Sriharsha, Lakshmi ^a   Lipton, Jeffrey H ^a   Pond, Greg ^a   Ma, Clement ^a   Raybardhan, Sumit ^a   Messner, Hans A ^a   Seki, Jack T ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Allogeneic stem cell transplant; Body surface area; Drug dosing

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BODY HEIGHT; BODY SIZE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SINUSOIDAL OBSTRUCTIVE SYNDROME; SURVIVAL TIME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; OBESITY, MORBID; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REFERENCE STANDARDS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75149140144     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155208101960     Document Type: Article

References (16)

1. Meloni G., Proia A., Capria S., Romano A., Trape G., Trisolini SM et al. Obesity and autologous stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplant 2001 ; 28: 365-367.
2. Grigg A., Harrun MH, Szer J. Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey. Leuk Lymphoma 1997 ; 25: 487-491.
3. Health implications of obesity.. National Institutes of Health Consensus Development Conference Statement. Ann of Intern Med 1985 ; 103 (6 (Pt 2). 1073-1077.
4. Pai MP, Paloucek FP The origin of ĝ€ĝ€ideal body weight equations. Ann Pharmacother 2000 ; 34: 1066-1069.
5. Himes JH, Bouchard C. Do the new metropolitan life insurance weight-height tables correctly assess body frame and body fat relationships? Am J Public Health 1985 ; 75: 1076-1079.
6. Metropolitan Life Insurance Company.. 1983 Metropolitan height and weight tables. Stat Bull 1983 ; 64: 3-9.
7. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM Prevalence of Overweight and Obesity in the United States, 1999-2004. JAMA 2006 ; 295: 1549-1555.
8. Navarro WH Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant 2003 ; 31: 961-966.
9. Cancer Therapy Evaluation Program, Common terminology criteria for adverse events, Version 3.0, DCTD, NCI, NIH, DHHS. ( http://ctep.cancer.gov ).
10. Dickson TMC, Kusnierz-Glaz CR, Blume KG, Negrin RS, Hu WW, Shizuru JA et al. Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biol Blood Marrow Transplant 1999 ; 5: 299-305.
11. Fleming DR, Rayens MK, Barrison J. Impact of obesity on allogeneic stem cell transplant patients: a matched case-controlled study. Am J Med 1997 ; 102: 265-268.
12. Nieto Y., Vaughan WP Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 2004 ; 33: 259-269.
13. Braess J., Pf¶rtner J., Kern W., Hiddemann W., Schleyer E. Cytidine Deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. Ann Hematol 1999 ; 78: 514-520.
14. Braess J., Wegendt C., Feuring-Buske M., Riggert J., Kern W., Hiddemann W. et al. Leukemic blasts differ from normal bone marrow mononuclear cells and CD34+ haematopoetic stem cells in their metabolism of cytosine arabinoside. Br J Haematol 1999 ; 105: 388-393.
15. Green B., Duffull SB What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J ClinPharmacol 2004 ; 58: 119-133.
16. Singhal S. Gordon L., Tallman M., Winter J., Williams S., Frankfurt O. et al. Submyeloablative allogeneic HSCT for hematologic malignancies: effect of body weight blood. 2005 abst. 2949.